8:35 am Chair’s Opening Remarks
8:40 am
Reflecting on Progress: Positive Clinical Readouts, Reverse Insights & Actionable Lessons for Glioblastoma Drug Developers
8:45 am Positive Clinical Updates on Vaccine-Based Approaches; Uncovering their Potential in Combination Therapy
Synopsis
- SurVaxM – a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine targeting surviving
- Phase IIa study of surVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma
9:15 am Outlining the Landscape in Paediatric Glioma & Delving Into Recent Successes
Synopsis
- Highlighting opportunities and challenges in developing therapeutics for elapsed or progressive paediatric low-grade glioma (pLGG).
- Navigating the dual challenges of a shifting landscape for response assessment criteria and changing views on minor response as evidence of clinical benefit.
- Targeting beyond the MAPK in paediatric glioma.
9:45 am Session Reserved for Novocure
10:00 am Morning Break & Speed Networking
Synopsis
The ideal opportunity to get face-to-face with many of the brightest minds working in the GBM field and introduce yourself to the attendees that you would like to have more in depth conversations with.
11:00 am Sharing an Update From Polaris – ADI-PEG 20 in Glioblastoma: Preclinical Studies & Phase I-II Results
Synopsis
- Review preclinical studies and phase I results
- Gain an update on phase II and phase II/III studies
- Discuss the initiation of ADI-PEG 20 into GBM agile
11:30 am Delving into a Clinical Update on Azeliragon for GBM- Implementable Lessons for Small Molecule Success
Synopsis
- In animal models of glioblastoma, azeliragon combined with radiation enhanced survival while overcoming the immunosuppressive tumor microenvironment
- Two phase II clinical trials of azeliragon, in combination with radiation with or without temozolomide, in newly diagnosed glioblastoma are in progress
- The effect of azeliragon on cerebral edema and ability to reduce dexamethasone dosing will be evaluated in the azeliragon studies in GBM
11:55 am
Surpassing the Blood Brain Barrier to Unlock the Potential of New Therapeutic Agents
12:00 pm Discovering Innovative Ultrasound Techniques to Open Up New Avenues for Treating Glioblastoma
Synopsis
- Discover the use of low intensity diffuse ultrasound with sonodynamic therapy to treat glioblastoma with both short and long-term effects
- Understand the suspected mechanism of action of sonodynamic therapy
- Understand and overcome the pitfalls in currently available brain cancer treatments
12:30 pm Exploring Local Drug Delivery in GBM: Enhanced Efficacy of ‘Compartment-Locked’ IL-12
Synopsis
- Evaluating the next generation of local therapies for brain cancer
- Discussing Compartment-Locked therapeutics with high retention and short systemic half-life
- Reviewing C-Locked IL-12 a promising new drug candidate
1:00 pm Lunch
1:55 pm
Optimizing Clinical Trial Design for GBM – Uncovering Past Lessons to Redefine Future Trial Outcomes
2:00 pm Gain Unrivalled Insights Into GBM-Specific Clinical Trial Rationale to Keep Ahead of the Curve
Synopsis
- Overview of the updated response criteria for glioblastomas and IDH-mutated gliomas: RANO 2.0
- Sharing therapeutic modality-specific advice on clinical trial design
- Analyzing novel endpoints for glioma trials
2:30 pm Going Beyond the Backbone; An Update on Recent Innovations in GBM Agile
Synopsis
- Integrating dose finding into GBM Agile
- Opportunities to consider the LE (learning environment) in AGILE
- Approaches to addressing combination therapy in GBM Agile
3:00 pm Expert-Led Advice on GBM Clinical Trial Structure to Set Your Trial Up for Success
Synopsis
- Discuss how to optimally leverage external control data to set your trial up for success
- Maximize the opportunity of adaptive platform trials for accelerated success
- Answer your burning questions around clinical trial rationale
3:30 pm A new liquid biopsy platform using Extracellular Vesicles to enhance multiomic insights into GBM
Synopsis
- Novel methodology (SPARCs) to isolate disease-associated Extracellular Vesicle (EV) subpopulations
- SPARCs technology enables significant enrichment of disease markers
- Practical translation for diagnostic and drug development application
3:40 pm Afternoon Break & Networking
3:55 pm
Reflecting on Progress: Positive Clinical Readouts, Reverse Insights & Actionable Lessons for Glioblastoma Drug Developers
4:00 pm Addressing Tumor Heterogeneity & Multiple Cellular States: Is Combination Targeted Therapy the Answer?
Synopsis
- Unveiling research into the complexity of tumor heterogeneity in GBM
- Reviewing preclinical data of one approach combining CT-179, an OLIG2 inhibitor, with EGFR inhibitors
- Exploring areas of potential research to identify and test scientifically rational combinations of targeted therapeutics
4:30 pm Panel Discussion: Is Prioritizing Combination Therapy Over Monotherapy the Most Promising Avenue for Overcoming Heterogeneity?
Synopsis
- Understand the shortfalls of key therapy types with regard to targeting tumor heterogeneity and how combination therapies can be used to strategically overcome these
- Combine drug treatments with radiotherapy or tumor treating fields
- Are combination therapies considered ‘too risky’ from a regulatory standpoint?
- Understand how the regulatory framework can best support the approval of combination therapies
5:30 pm Chair’s Closing Remarks
5:35 pm Scientific Poster Presentation
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of GBM experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.